Thomas Pressly, MD
Basic profileThomas Pressly is a Rheumatology/Immunology physician affiliated with Shriners Hospitals for Children - Shreveport. OpenAlex indexes 23 publications with 648 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AbbVieProgram year20256 paymentsResearch$11,677
- Amgen Inc.Program year202515 payments$373
- ABBVIE INC.Program year202516 payments$310
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
27.7%Gabapentinoids10.7%Gabapentin82%Pregabalin18%Part D≥99 patientsNonsteroidal Anti-inflammatory Drug5.4%Meloxicam100%Part D≥64 patients+ 7 more classes in this area
Cancer & immunology
20.4%Folate Analog Metabolic Inhibitor12.4%Methotrexate98%Methotrexate Sodium3%Part D≥122 patientsTNF inhibitor2.9%Enbrel43%Humira(Cf) Pen31%Humira(Cf)16%Humira9%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
20%Corticosteroid18.3%Prednisone100%Part D≥144 patientsProton pump inhibitor0.7%Omeprazole100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study
The Journal of Clinical Endocrinology & Metabolism
2010 - Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients
Rheumatology International
2005
Similar KOLs
Other experts from the same institution or the same specialty.
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”